Genmab A (GMAB) EBIT: 2018-2021
- Genmab A's EBIT rose 245.22% to $199.61 in Q2 2021 from the same period last year, while for Jun 2021 it was $323.60, marking a year-over-year decrease of 100.00%. This contributed to the annual value of $733.4 million for FY2020, which is 167.33% up from last year.
- Latest data reveals that Genmab A reported EBIT of $199.61 as of Q2 2021, which was up 3,606.64% from -$5.69 recorded in Q4 2020.
- In the past 5 years, Genmab A's EBIT registered a high of $25.5 million during Q4 2018, and its lowest value of -$11.7 million during Q2 2019.
- For the 3-year period, Genmab A's EBIT averaged around -$2.3 million, with its median value being $57.82 (2020).
- Per our database at Business Quant, Genmab A's EBIT plummeted by 107.92% in 2020 and then skyrocketed by 245.22% in 2021.
- Quarterly analysis of 4 years shows Genmab A's EBIT stood at $25.5 million in 2018, then plummeted by 100.00% to $71.86 in 2019, then plummeted by 107.92% to -$5.69 in 2020, then spiked by 245.22% to $199.61 in 2021.
- Its EBIT was $199.61 in Q2 2021, compared to -$5.69 in Q4 2020 and $57.82 in Q2 2020.
